摘要
目的研究多巴胺受体激动剂普拉克索治疗帕金森病(PD)非运动症状的临床疗效。方法给予29例PD患者普拉克索0.5mg每天3次(经过3周加量期)治疗,持续12个月;在治疗前和治疗12个月后进行汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)和简易精神状态检查(MMSE)量表评分,观察治疗前后感觉异常、便秘、排尿障碍、性功能障碍和肢体水肿的变化,以及不良反应。结果 PD患者治疗后HAMA、HAMD评分比治疗前显著降低(均P<0.01),而MMSE量表评分与治疗前的差异无统计学意义。治疗后感觉异常的患者(6例,20.7%)比治疗前(11例,37.9%)显著减少(P<0.05),治疗前后排尿障碍、便秘、性功能障碍及肢体水肿患者比例的差异无统计学意义。患者未出现明显不良反应。结论普拉克索能够减轻PD患者的焦虑、抑郁状态,改善其感觉异常的症状。
Objective To investigate the curative effect of dopamine receptor antagonist Pramipexole for treatment on non-motor symptoms of Parkinson＇s disease （PD）.Methods Continue for 12 months,Pramipexole has been administered with 0.5 mg 3/d （after 3 weeks phase of plus amount） to 29 patients with PD.Neuropsychological disorders as anxiety,depression and cognitive impairments were assessed by Hamilton anxiety scale （HAMA）,Hamilton depression scale （HAMD） and the mini mental state examination （MMSE） scale respectively at before and after 12 months treatment.Sensory dysfunctions,constipation,urinary dysfunction,sexual dysfunction,limb edema and adverse reactions were observed from pre-treatment to the end of the treatment.Results HAMA and HAMD scores were significantly reduced after treatment compared to pre-treatment （all P〈0.01）.The differences of MMSE scores before and after treatment had not statistical significance.After Pramipexole treatment,the patients with sensory dysfunctions （6 cases,20.7%） was significantly reduced than before （11 cases,37.9%） （P〈0.05）.The differences of rates of urinary symptoms,constipation,sexual dysfunction and limb edema had not statistical significance.Conclusion Pramipexole can reduce anxiety and depression,and also improve sensory dysfunction in PD patients.
出处
《临床神经病学杂志》
CAS
北大核心
2010年第4期299-301,共3页
Journal of Clinical Neurology
